TD Cowen Reiterates Buy Rating on Sutro Biopharma (STRO)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to TD Cowen Reiterates Buy Rating on Sutro Biopharma (STRO)

Piper Sandler Reiterates Overweight Rating on Sutro Biopharma (STRO)

September 17, 2024 5:54 AM EDT

Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $11.00 price target on Sutro Biopharma (NASDAQ: STRO).

The analyst comments "At ESMO, initial Phase I/II data on 4.3mg/kg q3W luvelta in combination with Avastin (bevacizumab) achieved impressive 56% (5/9) ORR in late-stage... More